For pharma BD teams in Korea and abroad
Korean biotech company cards, with sources and whether the company confirmed each item.
We organize Korean biotech assets in the order of the 20 questions BD asks in a first review.Ask the company directly about anything you want to know.
Sign up with your work email and confirm it by email.
Already signed up? Sign in
Annual subscription
What the annual subscription includes
The annual subscription covers all areas.Card access, sending questions and AI tool connection are for subscribed companies only.
What you see in each card
Sources and reference dates for each item
Korean and international sources together, with a source link and reference date on every item.
Korea
- DART filings
- KIPRIS patents
- Public agency records
- Korean press
- Company websites
International
- PubMed and Europe PMC papers
- ClinicalTrials.gov registrations
- EPO patents and legal events
- International press releases
Reading cards in English
Company confirmation, item by item
We distinguish, item by item, information the company has confirmed from information it has not. Not every item is confirmed by the company; unconfirmed information is marked 'Not confirmed by the company'. What the company has confirmed or corrected appears only if it consents to showing its submissions.
Asset information organized around 20 questions
Each asset follows the same set of 20 questions for an initial pharma BD review.
Gaps and disclosure scope
Items not found in the public sources Presigna checked are left empty and marked 'No public source found'. If the company consents to showing its submissions, questions where it has set a scope show that scope.
- Company answer
- Answers on request
- Answers after CDA
- Not answered via Presigna
Patent legal status
Where it can be checked, patents show their status alongside filing records: the KIPRIS status of Korean patents, such as granted, published, rejected or withdrawn, and the countries with a grant publication for overseas families.
What the subscription lets you do
Card access on the Presigna website
Find Korean biotech company cards in every area by modality, development stage and indication. Each card shows everything listed above.
Sending questions
Send your questions directly to the biotech, and the biotech answers them directly. Up to 5 a month to the same company.
- In preparation
AI tool connection (MCP)
Connect Presigna to the AI tool you use, and the AI finds assets, reads cards and sends questions. Connection is for business AI tools set not to train on your input.
Each annual subscription includes one account. You can add more accounts if you need them.
AI tool connection (MCP) is in preparation. We will announce the opening on screen and by email.
How it works
From free sign-up to reading cards
Sign up free to create your account. Areas of interest are optional, and you can change them in your account at any time.
You contract the annual subscription, which covers all areas.
Read Korean biotech company cards on the Presigna website, with a source and reference date for every item. Only paying companies Presigna has checked can see them.
Send the questions the company allows. If the company chooses to answer, you receive the answer it approved.
Sign the CDA on your own form, the usual way.
Principles
How we work
- Reading cards and permitted answers does not reveal your company's name. We share it with the biotech when you send a question or request a meeting or access to non-public materials.
- Information the company has not confirmed is marked 'not confirmed by the company'.
- Cards and answers are not on the public web, and there is no free trial.
- We do not recommend or introduce particular companies.
Create your pharma account.
Sign up free with your work email; the only extra step is an email check. Areas of interest are optional.
Already signed up? Sign in